INT157960

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 2007
Last Reported 2010
Negated 1
Speculated 4
Reported most in Body
Documents 11
Total Number 20
Disease Relevance 21.36
Pain Relevance 3.06

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (AQP4) plasma membrane (AQP4) transmembrane transport (AQP4)
cytoplasm (AQP4)
Anatomy Link Frequency
astrocytes 2
M-1 2
neocortex 1
vesicles 1
cerebellar cortex 1
AQP4 (Homo sapiens)
Pain Link Frequency Relevance Heat
Migraine 3 99.64 Very High Very High Very High
Multiple sclerosis 136 99.32 Very High Very High Very High
Glutamate 162 99.16 Very High Very High Very High
Glutamate receptor 12 96.84 Very High Very High Very High
addiction 24 96.20 Very High Very High Very High
Neuritis 64 95.96 Very High Very High Very High
Spinal cord 142 95.92 Very High Very High Very High
Inflammation 90 93.92 High High
Dopamine 56 90.92 High High
Demyelination 52 84.72 Quite High
Disease Link Frequency Relevance Heat
Neuromyelitis Optica 1098 99.80 Very High Very High Very High
Headache 7 99.64 Very High Very High Very High
Disease 584 99.56 Very High Very High Very High
Creutzfeldt Jakob Disease 70 99.52 Very High Very High Very High
Demyelinating Disease 270 99.32 Very High Very High Very High
Recurrence 206 98.16 Very High Very High Very High
Atrophy 49 97.84 Very High Very High Very High
Motor Neuron Diseases 133 96.44 Very High Very High Very High
Optic Neuritis 62 95.96 Very High Very High Very High
INFLAMMATION 93 93.92 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, the role of innervation in transcriptional regulation of AQP4 needs to be clarified.
Regulation (regulation) of AQP4
1) Confidence 0.48 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 0.73 Pain Relevance 0
Investigating the genetic role of aquaporin4 gene in migraine.
Spec (Investigating) Regulation (role) of aquaporin4 associated with migraine
2) Confidence 0.45 Published 2009 Journal J Headache Pain Section Title Doc Link 19209385 Disease Relevance 0.26 Pain Relevance 0.25
A significant proportion of NMO patients are seropositive for NMO-IgG, an autoantibody targeting aquaporin-4 (AQP4) water channel.
Regulation (targeting) of aquaporin-4 associated with neuromyelitis optica
3) Confidence 0.45 Published 2010 Journal J. Neuroimmunol. Section Abstract Doc Link 20728226 Disease Relevance 0.91 Pain Relevance 0.14
A significant proportion of NMO patients are seropositive for NMO-IgG, an autoantibody targeting aquaporin-4 (AQP4) water channel.
Regulation (targeting) of AQP4 associated with neuromyelitis optica
4) Confidence 0.45 Published 2010 Journal J. Neuroimmunol. Section Abstract Doc Link 20728226 Disease Relevance 0.91 Pain Relevance 0.14
The rapid down-regulation of EAAT2 and AQP4 induced by NMO-IgG in GFP-AQP4-expressing cells and colocalization of both proteins in cytoplasmic endocytotic vesicles within 10 min is consistent with a direct effect of IgG on a surface macromolecular complex.
Regulation (regulation) of AQP4 in vesicles associated with neuromyelitis optica
5) Confidence 0.41 Published 2008 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2571922 Disease Relevance 0.67 Pain Relevance 0.08
A focal increase of extracellular glutamate levels secondary to NMO-IgG–induced down-regulation of AQP4 may suffice to injure or kill oligodendrocytes that express calcium-permeable glutamate receptors (15, 22).
Regulation (regulation) of AQP4 in oligodendrocytes associated with neuromyelitis optica, glutamate and glutamate receptor
6) Confidence 0.41 Published 2008 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2571922 Disease Relevance 1.05 Pain Relevance 0.71
Suspension of azathioprine is followed by increase in AQP4-Ab levels and clinical attack
Regulation (followed) of AQP4
7) Confidence 0.41 Published 2008 Journal Brain Section Body Doc Link PMC2577801 Disease Relevance 0.79 Pain Relevance 0
In addition, in one of our patients, we found that AQP4-Ab levels rose selectively during clinical attack despite immunosuppressive treatment, while three other auto-antibodies, unrelated to NMO, declined at the same time or remained low.
Regulation (rose) of AQP4 associated with neuromyelitis optica
8) Confidence 0.41 Published 2008 Journal Brain Section Body Doc Link PMC2577801 Disease Relevance 0.99 Pain Relevance 0.04
In the largest series reported so far to our knowledge, we quantified AQP4 antibodies in patients with NMO versus various other diseases, and showed that the aquaporin 4 water channel is a target antigen in a majority of patients with NMO.
Regulation (target) of aquaporin 4 associated with neuromyelitis optica and disease
9) Confidence 0.27 Published 2007 Journal PLoS Medicine Section Abstract Doc Link PMC1852124 Disease Relevance 1.68 Pain Relevance 0.23
Additional research will determine whether AQP4 is the only protein targeted by autoantibodies in NMO and whether this targeting is a critical part of the disease process.


Spec (whether) Regulation (targeted) of AQP4 associated with neuromyelitis optica and disease
10) Confidence 0.27 Published 2007 Journal PLoS Medicine Section Abstract Doc Link PMC1852124 Disease Relevance 1.06 Pain Relevance 0.14
NMO-IgG binding to primary astrocytes induces AQP4 modulation and complement activation
Regulation (modulation) of AQP4 in astrocytes associated with neuromyelitis optica
11) Confidence 0.25 Published 2008 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2571922 Disease Relevance 0.99 Pain Relevance 0.27
No correlation between CD19 cell count and AQP4-Ab values was found in those patients not treated with rituximab (data not shown).
Neg (No) Regulation (values) of AQP4
12) Confidence 0.24 Published 2008 Journal Brain Section Body Doc Link PMC2577801 Disease Relevance 0.62 Pain Relevance 0
This hypothesis is supported by the significant higher number of relapses and the longer disease duration in patients with M-1 and M-23 IgG compared to patients who target only M-23 AQP4.
Regulation (target) of AQP4 in M-1 associated with disease and recurrence
13) Confidence 0.24 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2864757 Disease Relevance 0.84 Pain Relevance 0.06
To summarize, weaker binding was observed to full length AQP4, which is also evident from the lower titer values of M-1 AQP4-IgG (Table 1).


Spec (evident) Regulation (values) of AQP4-IgG in M-1
14) Confidence 0.24 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2864757 Disease Relevance 1.91 Pain Relevance 0.19
Increased AQP4 immunoreactivity was observed in all these patients, particularly in the cerebral neocortex and cerebellar cortex.
Regulation (immunoreactivity) of AQP4 in cerebellar cortex
15) Confidence 0.21 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 1.41 Pain Relevance 0.04
AQP4 immunoreactivity was present in the cell bodies and processes of protoplasmic astrocytes in SSE and around cell bodies and processes of hypertrophic astrocytes in PE-type CJD.
Regulation (immunoreactivity) of AQP4 in astrocytes associated with creutzfeldt jakob disease
16) Confidence 0.21 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 1.45 Pain Relevance 0.03
In addiction, Lucchinetti [56] and Roemer [80] and their groups have independently performed detailed comparative study between NMO and MS lesions: in particular, in contrast to NMO, they revealed that AQP4 immunoreactivity was variable in MS lesions (AQP4 is diffusely increased in the white matter of active lesions, whereas chronic inactive lesions are devoid of AQP4).
Regulation (immunoreactivity) of AQP4 in white matter associated with addiction, neuromyelitis optica and multiple sclerosis
17) Confidence 0.21 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 1.53 Pain Relevance 0.35
The increased sensitivity of AQP4 assays compared with NMO-IgG testing suggests that AQP4 is the main, or possibly the only, target for NMO-IgG [41, 96].
Spec (possibly) Regulation (target) of AQP4 associated with neuromyelitis optica
18) Confidence 0.21 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 1.51 Pain Relevance 0.15
These findings imply that modulation of AQP4 could be used therapeutically in the treatment of PD.


Regulation (modulation) of AQP4 associated with disease
19) Confidence 0.21 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 0.63 Pain Relevance 0.20
Increased AQP4 immunoreactivity was observed in all these patients, particularly in the cerebral neocortex and cerebellar cortex.
Regulation (immunoreactivity) of AQP4 in neocortex
20) Confidence 0.07 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 1.41 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox